Dear Clients and Friends,
It’s been quite a while since we posted a coronavirus-related update. However, given the Delta variant and the recent uptick in the case count, it seems worthy of our attention once again. The data below comes from reliable scientific sources such as Yale University, Johns Hopkins University, the CDC, etc. If you don’t believe in science, or if you think that the vaccine has tiny little robots in it, or if you think that the earth is flat, stop reading. This article is not for you.
[This article was written 8 days ago, and the data is already somewhat outdated. Over the last one week, the daily case count has more than doubled.]
It’s important to know that the Delta strain is at least 225% more contagious than the original COVID-19 strain, and is reported by the CDC to be the most contagious respiratory illness currently on planet earth. Also, an unvaccinated person is likely to infect 60% more unvaccinated people with the Delta strain than with the original strain. Lastly, the Delta variant is far more problematic for children, whereas the original strain was mostly a concern for the elderly.
The most recent data clearly shows the Delta variant of the virus has led to a new wave of infection growth. Although the effect has been limited so far, the medical risks are back on the table. The economic damage has been limited, as the country has reopened and the economy is growing. But here, too, there are signs risks may be rising.
Part of what’s driving this faster infection growth is the slowing rate of vaccinations, which has left large proportions of the country vulnerable to the Delta variant. Another major driver looks to be the reopened economy. While this reopening has led to faster growth, it has also led to more public activity and exposure. And with the wide abandonment of masks, unvaccinated people are more at risk than ever.
The good news is that we may be starting to see vaccination rates rising again, which should help control the risks. Conditions at the national level remain stable, as most of the outbreaks so far have been localized, as expected. With more vaccinations and appropriate public policy, those outbreaks are containable, which is more good news.
From an economic perspective, the news remains good as rising infection rates have not yet translated into more economic restrictions. Job growth remains strong, layoffs continue to trend down, and confidence and spending are high. The major economic problems remain those of success. While medical risks are rising, the economic news is positive—and is likely to stay that way.
Despite the rising medical risks, the overall outlook remains positive, although we do need to pay attention. So far, markets are clearly discounting the risks, as they remain close to all-time highs. Plus, with corporate earnings continuing to do well, there may well be more upside ahead. Let’s take a look at the details.
Case Growth Levels on the Rise
New cases per day. The most obvious metric for tracking the virus is daily new cases. Case growth has risen over the past three weeks and is now back to levels from mid to late May. At this point, another national infection wave looks unlikely, as most of the outbreaks are restricted to locales with low vaccination levels, but the risks are increasing. This may well be due to the spread of the more contagious Delta variant and raises the risks of a further worsening of the trend.
The seven-day average of new cases per day was 26,704 on July 14, up from 13,618 two weeks earlier, an increase of 96 percent. Case growth is now at levels we last saw in mid to late May, erasing the improvement in June and early July. The trend in infection growth is clearly back up.
Hospitalizations. We also see the deterioration in the hospitalization data. On July 10, there were 15,286 people hospitalized, up from 12,223 two weeks prior, an increase of 25 percent. Hospitalizations typically lag case data, so a further substantial increase in hospitalizations is likely here as well.
Testing news. The testing news is also getting worse. Overall testing numbers have spiked back up, which is reasonable given the increase in the number of cases, and the positive test rate has now risen to close to 5 percent. This is a level that signals widespread infection exposure and one we have been below since April. This is a worrying development.
Source: Johns Hopkins University
Vaccinations. The deterioration in the medical news is at least partially due to a slowdown in vaccinations. As the medical news improved, many people elected not to get vaccinated and to abandon policies such as mask-wearing. While more than 55 percent of the U.S. population has had at least one dose of the vaccine and 48 percent are fully vaccinated, the rate of vaccinations has slowed sharply. We may now be seeing the effect of the slower vaccination rate in a rising new case rate in many areas. That said, we do seem to have hit containment levels nationally, and herd immunity in many states is now within reach. Much of the current infection growth is in low vaccination areas, which may limit the national impact.
Job Growth Picking Up, Economy Expanding
Despite the medical news, the economic data continues to get better overall. Job growth continues to improve, while layoffs continue to edge down and job openings to grow. Consumer and business confidence remain high, and spending and investment are healthy. Overall, the economy has now reopened, and growth continues. Many of the problems we do observe are those of success, which are the kind of problems we want to have. As employment continues to increase and supply chains to heal, we are very likely through the worst of the economic impact of the pandemic.
Financial Markets Hold Close to Highs
Markets saw more new all-time highs in the past month, supported by the good news on the medical and economic fronts, as well as much better-than-expected corporate earnings reports. Since then, the stock market has bounced around, looking for the next set of good news, but it remains near those highs. While the medical risks are rising, so far at least, both the economy and markets have been unaffected.
A Solvable Problem?
We have seen the medical risks rise in the past several weeks, as infection growth has accelerated again. Those risks remain focused in areas with low vaccination rates, however, and the risks of a national shutdown are low. So far, the country remains open and the economy is growing, and that will likely continue unless medical conditions get much worse. Markets continue to do well and may have more upside ahead.
Even as we keep an eye on the risks, we are still at a place where they are specific rather than systemic. We are seeing localized outbreaks but likely not national ones. We may see glitches in some markets (e.g., labor or supply chains). But, in general, conditions are improving. This shift is good news, as it means the difference between specific problems and a general shutdown, whether medical or economic. Right now, the good news is that the specific problems we're seeing, and are likely to see, will be solved. The better news is that the more of those specific problems that get solved, the less risk—and the sooner we get back to normal.
Although the risks are rising, these are problems we know how to solve. Therefore, we are still in a much better place than we were only a couple of months ago. While there are very real risks at the national level, we are still within reach of “normal.” The largest threats involve distrust in science and in the vaccine. Statistically, more conservatives question the vaccine than liberals. So, I’ll say this: if Trump took the vaccine, so can you. Regardless of my political affiliation, if that comment encourages someone to take science more seriously than their Facebook friends, I’ll keep saying it. If anyone tells you they don’t want the vaccine because they don’t know what’s in it, ask them what ingredients are in their toothpaste other than fluoride.
Until then, stay safe and get vaccinated, believe in science, and have a lovely weekend.
Matt and the Crew at MORWM
Matthew Ramer, AIF®
Principal, Financial Advisor
MOR Wealth Management, LLC
1801 Market Street, Suite 2435
Philadelphia, PA 19103
P: 267.930-8301 | c: 215-694-4784 | f: 267.284.4847 |
601 21st Street, Suite 300
Vero Beach, FL 32960
P: 772-453-2810
matthew.ramer@morwm.com | www.morwm.com
The majority of this content was written and distributed MOR Wealth Management, all rights reserved. Securities and advisory services offered through Commonwealth Financial Network, Member FINRA/SIPC, a registered investment adviser. Fixed insurance products and services offered through CES Insurance Agency.